Karuna Therapeutics, Inc.

Headquarters: Boston, MA, United States

Employees: 118

CEO: Dr. Steven M. Paul M.D.


Market Cap

$11.94 Billion

USD as of Jan. 1, 2024

history Market Cap History

Karuna Therapeutics, Inc. market capitalization over time

Evolution of Karuna Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Karuna Therapeutics, Inc.

Detailed Description

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.


"Bulls make money...
Bears make money...
Pigs get slaughtered!"

Stop guessing, unlock Financial AI.

(Don't be a pig.)

Stocks & Indices

Karuna Therapeutics, Inc. has the following listings and related stock indices.

Stock: NASDAQ: KRTX wb_incandescent



33 Arch Street

Suite 3110

Boston, MA 02110

United States

Phone: 857 449 2244